

Press release

Stockholm June 18th, 2019

Biolamina and Spiber Technologies sign exclusive sales and marketing deal for unique Biosilk products

BioLamina has for the last 10 years been marketing reagents that make primary cell culture simpler and more reliable. Three-dimensional (3D) culture technologies has become a megatrend within the Life Science & Med Tech industry, to make more complex tissue-models. Through years of collaboration and a licensing agreement with the Stockholm based company Spiber technologies, BioLamina now offers a biorelevant way to culture primary cells like stem cells in 3D.

BioLamina develops and markets high-quality products supporting stem cell research and drug development to enable novel therapies. BioLamina products are used today around the world in more than 45 countries, but we have lacked a proper tool to culture cells in 3D. After several years of collaboration with Spiber technologies, we are finally able to provide a unique product based on their recombinant silk-protein combined with our Biolaminin proteins. Together these products create a novel 3D environment that offers the biorelevance from Biolaminins and the 3D support from Biosilk.

The Biosilk products will be launched at the International Society of Stem Cell Research annual conference in Los Angeles in the end of June. The products will then be available for our global customers.

"We are super excited about these new products! Everyone we have talked with about the product already say it sounds so much better than anything else available on the market today", says Kristian Tryggvason, CEO of BioLamina. "We are so proud to be able to offer these great product developed in My Hedhammars laboratory at KTH. They have done an amazing job!" My Hedhammar, Spiber technologies scientific founder and professor at KTH continues, "It has been so fun to collaborate with BioLamina and we are so excited to get our products out on the market after so many years developing the products."

For more information, please contact:

BIOLAMINA AB
Kristian Tryggvason, CEO Telefon +46 70 743 22 33
Email: communications@biolamina.com



ABOUT BIOLAMINA AB

BioLamina commercializes innovations based on research from the Karl Tryggvason laboratory at Karolinska Institute and Duke-NUS, solving technical problems within culturing of embryonic stem cells and other types of primary cells. Many of the products manufactured and sold by BioLamina are based on human recombinant proteins called laminins. The laminins provide cells with an environment mimicking their natural location in the cell culture dish. Different laminin isoforms are expressed in different tissues in the body, hence many different cell types can thrive on laminins. Laminins and other innovations together solve many of the technical problems in research such as reproducibility and low cell quality and therefore help the development of new cell therapies. BioLamina was founded in 2009.

For more information: www.biolamina.com

ABOUT SPIBER Technologies AB

Spiber Technologies AB is a research-intensive biotech company based in Stockholm. Spiber develops, produces and commercializes products based on recombinant spider silk proteins. The main applications for these products are within MedTech, primarily cell culture including stem cells and regenerative medicine.

For more information: www.spiber.se

